Lilium downgraded to Underweight from Equal Weight at Barclays

Barclays analyst David Zazula downgraded Lilium to Underweight from Equal Weight with a price target of $1, down from $2. While Lilium maintains significant long-term potential if regulatory approval can be achieved, the potential for further dilution "warrants caution," Zazula tells investors in a research note. Given the company’s "sizable unfunded spending needs through certification," equity holders should be conscious of additional issuance and corresponding reduction in ownership stake, says the analyst.